News

Fierce Pharma1d
Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
The Lancet18h
Transforming COPD management: the role of dupilumab
Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...
GlobalData on MSN1d
First subject dosed in Upstream Bio’s Phase II trial of verekitug for COPD
Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...
Physician's Weekly1d
Addressing Patients’ Ongoing COPD Symptom Burden & Care Gaps
A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...
Medpage Today on MSN1d
Switch to Dry-Powder Inhaler Worsened COPD, Asthma Patient Outcomes
Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...